17 February 2020
Oncode Oncology Bridge Fund announces two Entrepreneurs in Residence
The Oncode Oncology Bridge Fund, launched by Oncode BV, is proud to announce the appointment of two Entrepreneurs in Residence (EIR’s). Dr. Markwin Velders (click for bio) brings over 25 years of research experience in the field of tumor immunology and over 18 years of management experience in biotechnology companies. Dr. Allard Kaptein (click for bio) is the Managing Director of Genase Therapeutics. Prior to that, he was co-founder of Acerta Pharma, spinning out the covalent BTK inhibitor series from MSD into Acerta Pharma.
17 February 2020
Oncode Institute appoints Chris De Jonghe as its new Valorization Director
Oncode Institute today announced that its Supervisory Board has appointed Chris De Jonghe as Valorization Director. Chris will start at Oncode Institute on May 4th and assumes her role as Valorization Director and all responsibilities on June 1st. Angus Livingstone, Oncode’s founding Valorization Director will stay with Oncode Institute until May 31st.
11 February 2020
Five Oncode Investigators win the first Ammodo Science Award for groundbreaking research
The winners of this award are the group behind the research project Guardians and Caretakers of the Genome based at the Erasmus MC and the research group Social Educational Neuroscience Amsterdam (SENSA) of the Vrije Universiteit Amsterdam. They each receive a cash prize of 1.2 million euros which they will use to explore new areas of research. Oncode Investigators Jurgen Marteijn, Wim Vermeulen, Roland Kanaar, Jan Hoeijmakers and Miao-Ping Chien are part of the Erasmus MC research project.
26 January 2020
Oncode researchers gain access to Organoid technology thanks to collaboration with KNAW
Thanks to an agreement between the Royal Netherlands Academy of Arts and Sciences (KNAW) and Oncode Institute, the organoid technology will become available to all 800+ cancer researchers that are part of Oncode. The KNAW collaborates with its institutional partner UMC Utrecht on organoid technology. Thanks to this agreement with Oncode, researchers receive a license to conduct research on organoids for the first time in the Netherlands.
3 February 2020
World cancer day: the importance of patient engagement within cancer research
- Open article for English - 4 februari is het wereldkankerdag. Erica van Wuijtswinkel, patiëntvertegenwoordiger bij de Raad van Toezicht van Oncode Institute, legt uit waarom patiëntenparticipatie zo belangrijk is binnen kankeronderzoek. Ze bespreekt ook hoe zij haar rol binnen Oncode Institute invult en hoe Oncode patiëntenparticipatie heeft ingebed in de organisatie.
Fundamental science, clinical testing and a sharp mind for market opportunities: at Oncode we bring it all together to create impact for patients.
Scroll for more